Evidence map›Paper›PMID 40550564›Full record

ArticleJournal for immunotherapy of cancer2025

Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception.

Xinyuan Chen, Shanyue Sun, Shuofeng Li, Shuangni Yu, Jie Chen, Xianlong Chen

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. [Research progress in clinical pathology and molecular mechanisms of pancreatic adenosquamous carcinoma].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyuan ChenDepartment of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China.ORCID http://orcid.org/0009-0007-9191-2521
Shanyue SunShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Shuofeng LiDepartment of Liver Surgery, Peking Union Medical College Hospital, Beijing, Beijing, China.ORCID http://orcid.org/0000-0003-2747-9501
Shuangni YuDepartment of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China.
Jie ChenDepartment of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China.ORCID http://orcid.org/0000-0002-2658-9525
Xianlong ChenDepartment of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China xlchen1995@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic adenosquamous cancer (PASC) is an extremely rare subtype of pancreatic cancer characterized by a poorer prognosis and higher likelihood of metastasis compared with the more prevalent pancreatic ductal adenocarcinoma (PDAC). Although genomic changes during PASC tumorigenesis have been documented, the corresponding alterations in the tumor immune microenvironment (TIME) remain inadequately elucidated. Therefore, this study aims to analyze the immune landscape of PASC by employing multiplex immunohistochemistry (mIHC) and digital image analysis.

methodsIn this study, we analyzed four independent cohorts comprising 120 patients with PASC and 386 patients with PDAC. We employed mIHC to quantify three in situ panels of immuno-oncology-related biomarkers at subcellular resolution. We then used five samples to perform laser capture microdissection, RNA sequencing, and whole-exome sequencing to explore the underlying mechanisms of the compartment-specific immune phenotypes in PASC.

resultsOur findings revealed a more immunosuppressive TIME in PASC compared with PDAC, characterized by a decreased abundance of T cells. Immune cell types indicative of enhanced immune surveillance, including cytotoxic and memory T cells and antigen-experienced T cells, were present at significantly lower densities in PASC compared with PDAC. Conversely, some immunosuppressive macrophage phenotypes exhibited increased distribution in PASC. Immunosuppressive immune cells (ICs) were abundant, enriched within stromal regions, highly heterogeneous across tumors, and exhibited distinct distributions between squamous cell (SQC) and adenocarcinoma (ADC) compartments in PASC. Notably, the TIME of SQC compartments harbored more exhausted T cells compared with synchronous ADC compartments, indicating attenuated immune surveillance during squamous transformation. Transcriptomic profiling of microdissected SQC and ADC regions revealed immune exhaustion signatures and downregulated T-cell differentiation pathways in SQC compartments, alongside altered antigen presentation machinery and elevated tumor mutational burden, suggesting squamous-specific tumor-associated antigens with potential immunotherapeutic relevance. Beyond differences in IC density, we observed closer spatial proximity of CD45RO

conclusionOur study advances the understanding of PASC by providing updated insights into its immunoenvironmental features. These findings underscore the potential of targeting immune checkpoint pathways, particularly the TIGIT/CD155 and PD-1/PD-L1 axes, as a therapeutic strategy for PASC.

Indexed as

Carcinoma, AdenosquamousCell Transformation, NeoplasticImmunologic SurveillancePancreatic NeoplasmsAgedBiomarkers, TumorCarcinoma, Pancreatic DuctalFemaleHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedTumor MicroenvironmentBiomarkers, TumorPathologyTumor Microenvironment

Identifiers

PMID40550564
PMCPMC12186043

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.